Veracyte, Inc. (VCYT) Stock Analysis
Last updated Sep 8, 2026
Health Check
Last analyzed Sep 7, 2026
- Financial Health 85
- Profitability 95
- Business Quality 75
- Balance Sheet 65
- Cash Flow 80
Why this rating?
Health 82/100 — Elite Quality
Worth tracking, but timing is mixed — not a clear setup yet.
Company overview
Veracyte, Inc. (VCYT) is a Diagnostics & Research company in the Healthcare sector. Compound Radar rates Veracyte, Inc. 82/100 (Elite Quality) due to high business quality, strong revenue growth, and manageable leverage.
Investment profile
- Quality High
- Growth Strong
- Balance Sheet Adequate
- Valuation Fair
Financial highlights
Valuation
- P/E 30.32
- Forward P/E 21.79
- EV/Revenue 5.29
Profitability
- Revenue Growth 15.5%
- Gross Margin 73.8%
- Operating Margin 15.3%
- Net Margin 20.4%
- ROE 8.8%
Financial strength
- Cash $485.23M
- Debt $40.11M
- Net Cash $445.13M
- Free Cash Flow $126.63M
- Current Ratio 9.16
Similar companies
Peers in Diagnostics & Research, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Illumina, Inc. Diagnostics & Research ILMN$211.06 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- CareDx, Inc. Diagnostics & Research CDNA$50.31 73 Health 73 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Qiagen N.V. Diagnostics & Research QGEN$42.38 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Danaher Corporation Diagnostics & Research DHR$205.23 68 Health 68 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Quest Diagnostics Incorporated Diagnostics & Research DGX$235.50 67 Health 67 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Sotera Health Company Diagnostics & Research SHC$18.59 67 Health 67 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Revvity, Inc. Diagnostics & Research RVTY$127.08 66 Health 66 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- BillionToOne, Inc. Diagnostics & Research BLLN$99.06 65 Health 65 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
FAQ
How Compound Radar scores and tracks Veracyte, Inc. (VCYT).